Combining advanced imaging techniques to improve prostate cancer detection
Official title: Combining High-frequency Micro-ultrasound Target Biopsy and Multiparametric MRI Target Biopsy - Does it Increase the Detection Rate of Clinically Significant Prostate Cancer? A Prospective, Interventional, Single Centre, Randomized Controlled Trial
Run by Salzburger Landeskliniken · NCT06579911 · Data updated 2026-11-12
This study is testing if using advanced imaging techniques together can help find more serious prostate cancers in men better than standard biopsy methods.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 99 Years |
| Sex | Men only |
| Enrollment | 400 (estimated) |
| Sponsor | Salzburger Landeskliniken Academic / other |
| Locations | 1 site (Salzburg, State of Salzburg) |
| Status | Recruiting |
| Started | November 1, 2023 |
| Main results expected | November 1, 2027 |
| Study ends | January 1, 2028 |
| Registry record updated | June 9, 2026 |
| Trial ID | NCT06579911 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are men with suspected clinically significant prostate cancer indicated by elevated PSA levels or suspicious digital rectal examinations.
✕Probably not a fit
Patients who already have a confirmed diagnosis of prostate cancer or those with very high PSA levels may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to evaluate whether the combination of high-frequency micro-ultrasound and multiparametric MRI-targeted biopsy can enhance the detection of clinically significant prostate cancer compared to standard biopsy methods. Participants will undergo a series of procedures including high-frequency micro-ultrasound examination, multiparametric MRI-targeted biopsy, and systematic biopsy. The study will assess if this new approach can identify more significant cancers without increasing the detection of less serious forms. The findings could lead to improved diagnostic accuracy for men suspected of having prostate cancer.
Why it matters
Potential benefit: If successful, this study could lead to more accurate detection of clinically significant prostate cancers, potentially improving patient outcomes.
How similar studies have gone: While this approach is innovative, similar studies have shown promise in improving cancer detection rates, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Men with suspected clinically significant prostate cancer, identified by the rise in PSA level, suspicious digital rectal examination or both and pathologic multiparametric MRI of the prostate (\>= PI-RADS III) Exclusion Criteria: * Patients with histopathologic proven prostate cancer * PSA \> 20 ng/ml * Finding in digital rectal examination \>= cT2c * Untreated bacterial infection of the prostate * Untreated coagulopathy
Where it's running
-
Uniklinikum Salzburg, Department for Urology and Andrology
Salzburg, State of Salzburg, Austria Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Biomarker t6A for Early Detection of Bacterial Infection in Newborns
A bi-center study tests whether the t6A biomarker can quickly detect early-onset sepsis in newborns who need blood tests.
-
How vegan, vegetarian, or omnivorous diets relate to blood levels of brain proteins NfL and GFAP
This study will test whether following a vegan, vegetarian, or omnivorous diet changes blood levels of the brain proteins NfL and GFAP in healthy adults aged 18–40.
-
Using Nivolumab to treat advanced skin cancer
This study is testing if the drug Nivolumab, alone or with another drug called Relatlimab, can help people with advanced skin cancer feel better and improve their condition.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.